SecBot SecBot
Biotech Drug Report Generated Nov 12, 2026

HEPAGAM

KMDA·Kamada Ltd.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved and marketed
Time to market
Already approved and commercialized. No additional regulatory steps are needed for the current indication.
Why 4/10
HEPAGAM is an already-approved, marketed product with no pending regulatory decision or pivotal readout. It is one of six FDA-approved products in Kamada's diversified portfolio, not the sole value driver. The next hard catalyst for the stock would be the full-year 2026 earnings report (early 2027), which is a quarterly earnings event, not a drug-specific binary. Per the rubric, an approved drug with no pending regulatory decision scores 3-5; a 4 reflects that HEPAGAM contributes to a growing commercial portfolio but is not a standalone binary catalyst.
Actionable Insight NEUTRAL

HEPAGAM is a steady commercial product within a diversified portfolio, not a binary catalyst. Kamada's next major event is the Q4/full-year 2026 earnings report in early 2027, where investors will watch for continued demand trends across the product portfolio including HEPAGAM. The stock trades at $8.13 with a mean analyst target of $13.50, but the recent insider selling and institutional trimming warrant monitoring.

Price Chart

Loading chart...

Executive Summary

HEPAGAM (HEPAGAM B) is an FDA-approved hepatitis B immune globulin product marketed by Kamada Ltd. (NASDAQ: KMDA), an Israeli biopharmaceutical company focused on plasma-derived therapies. The drug provides passive immunity against hepatitis B for post-exposure prophylaxis. It is one of six FDA-approved plasma-derived products in Kamada's commercial portfolio and contributed to the company's record financial results in the first nine months of 2026. As an already-approved, marketed drug with no pending regulatory catalysts, HEPAGAM is a steady commercial contributor rather than a binary event driver for the stock.

How It Works

HEPAGAM is a plasma-derived antibody therapy (immune globulin) that provides immediate, passive immunity against the hepatitis B virus. It is extracted from the blood plasma of donors who have high levels of hepatitis B antibodies, and when injected into a patient, it neutralizes the virus and prevents infection after exposure.

Trial Status

HEPAGAM B is an FDA-approved, commercially marketed product. It is one of six FDA-approved plasma-derived biopharmaceutical products in Kamada's commercial portfolio, alongside KEDRAB (rabies immune globulin), VARIZIG (varicella immune globulin), CYTOGAM (cytomegalovirus immune globulin), WINRHO SDF (Rho(D) immune globulin), and GLASSIA (alpha-1 proteinase inhibitor). Kamada reported that stronger demand for KEDRAB, VARIZIG, and HEPAGAM supported its record financial performance in the first nine months of 2026.

The Two-Sided Case

▲ Bull Case4
HEPAGAM is part of a growing commercial portfolio that drove Kamada to record-high first nine months 2026 results, with the company raising full-year guidance to $205M-$208M in revenue.
Kamada's plasma-derived product portfolio benefits from strong demand trends, with HEPAGAM specifically cited alongside KEDRAB and VARIZIG as supporting the company's performance in 2026.
Analyst consensus is strongly bullish on KMDA (3 strong buy, 5 buy, 1 hold) with a mean price target of $13.50, implying roughly 66% upside from the $8.13 close on November 11, 2026.
Stifel raised its price target to $12 on November 9, 2026, maintaining a Buy rating.
▼ Bear Case4
HEPAGAM is a mature, approved product in a competitive hepatitis B immune globulin market with limited differentiation, facing potential competition from other HBIG products and hepatitis B vaccines.
HEPAGAM is just one of several products in Kamada's portfolio and does not individually drive the stock's valuation, limiting its impact as a catalyst.
Insider selling was detected in the 90-day lookback, including significant sales by director David Tsur (over 162,000 shares sold on September 8, 2026), which may signal insider caution.
Several institutional holders trimmed positions in Q2 2026, including Envestnet (trimmed 67%) and Marshall Wace (trimmed 50%).

Upcoming Catalysts

  • No HEPAGAM-specific binary catalysts are scheduled. The drug is already approved and marketed. Kamada's next company-level catalyst is the Q4 2026 / full-year 2026 earnings report, expected in early 2027.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Kamada Ltd. PRESS-RELEASE KMDA ·Originating report

Sources · 4

Hover a chip for the title
1 ad-hoc-news.de2 finanznachrichten.de3 markets.businessinsider.com4 pharmabiz.com